United States Cancer Gene Therapy Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global cancer gene therapy market size reached US$ 3.36 Billion with rise of US$3.97Billion in 2024 is expected to reach US$ 19.97Billion by 2033, growing at a CAGR of 19.8%during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ In June 2025, BioNTech announced an $11 billion partnership with Bristol Myers Squibb to co-develop BNT327, a bispecific antibody targeting two cancer cell receptors. This collaboration aims to rival Merck's Keytruda and is currently undergoing over 20 clinical trials, including two in late-stage development.

✅ In May 2025, BioNTech acquired CureVac in an all-stock deal valued at approximately $1.25 billion. This strategic move enhances BioNTech's capabilities in developing mRNA-based cancer immunotherapies, reflecting its long-term focus on oncology beyond its COVID-19 vaccine success.

✅ In May 2025, BioNTech announced plans to invest up to £1 billion ($1.33 billion) in the United Kingdom over the next decade to expand its research and development activities. This investment includes enrolling up to 10,000 patients in clinical trials for personalized cancer therapies by 2030.

Japan: Recent Industry Developments

✅ In September 2025, the Japan Entry Acceleration Program (JEAP) announced opportunities for gene therapy startups to enter the Japanese market. This initiative aims to foster innovation and collaboration in regenerative medicine and cell and gene therapy.

✅ In August 2025, Eisai Co., Ltd. received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare for its anticancer agent Tazemetostat, intended for the treatment of unresectable INI1-negative epithelioid sarcoma.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cancer-gene-therapy-market?sb

Cancer Gene Therapy is an advanced treatment that modifies a patient's genes to target and destroy cancer cells or boost the immune system. It includes techniques like gene addition, gene silencing, CAR-T immunotherapy, and oncolytic viruses, offering precise, personalized cancer care with fewer side effects than traditional therapies.

Recent Mergers and Acquisitions

United States: Recent M&A in Cancer Gene Therapy

✅ In May 2025, Helix BioPharma completed the acquisition of oncology assets from Laevoroc Immunology AG for CHF 5.3 million. This strategic move aims to bolster Helix's portfolio in cancer immunotherapy, enhancing its research and development capabilities.

✅ In March 2025, Bristol Myers Squibb acquired 2seventy bio for approximately $286 million in cash. This acquisition, which includes an 88% premium over 2seventy's last closing price, aims to consolidate Bristol Myers' position in CAR T-cell therapies, particularly enhancing its Abecma treatment for multiple myeloma. The deal is expected to close in Q2 2025.

✅ In January 2025, Bluebird Bio agreed to be acquired by private equity firms Carlyle Group and SK Capital Partners in a deal valued at up to $96 million. The transaction includes an initial cash payment with contingent value rights, providing Bluebird with capital to support its gene therapies for various diseases and avoid loan default.

Japan: Recent M&A in Cancer Gene Therapy

✅ In August 2025, Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, announced the acquisition of Switzerland's Araris Biotech for up to $1.14 billion. Araris specializes in next-generation antibody-drug conjugates targeting tumors, aligning with Taiho's strategy to expand its oncology pipeline.

Key Players:

-> Novartis AG, Pfizer, Adapt immune Therapeutics, Bluebird Bio, Inc., Krystal Biotech, Inc., Regulus Therapeutics, Biogenera and among others.

Growth Forecast Projected:

The Global Cancer Gene Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Cancer Gene Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=cancer-gene-therapy-market

Key Segments:

By Technique: In vivo Gene Therapy, Ex vivo Gene Therapy

By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer, Others

By Application: Brain Cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, Liver Cancer, Others

By End-User: Hospitals, Cancer Centers, Others

Regional Analysis for Cancer Gene Therapy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Cancer Gene Therapy producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Cancer Gene Therapy revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-gene-therapy-market?sb

FAQ

What is the current size of the Cancer Gene Therapy Market?

A: In 2024, the Cancer Gene Therapy Market was valued at US$3.97Billion, reflecting its strong industry presence.

Q2: How large is the Cancer Gene Therapy Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Cancer Gene Therapy Market will grow to around US$ 19.97Billion , demonstrating significant expansion.

Q3: What is the growth rate of the Cancer Gene Therapy Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 19.8% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.